American International Group Inc. bought a new position in Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,585 shares of the company’s stock, valued at approximately $93,000.
Several other large investors also recently modified their holdings of the stock. Citigroup Inc. purchased a new stake in Y-mAbs Therapeutics in the 4th quarter worth $37,000. Strs Ohio purchased a new position in shares of Y-mAbs Therapeutics during the fourth quarter valued at about $38,000. Point72 Asset Management L.P. purchased a new position in shares of Y-mAbs Therapeutics during the third quarter valued at about $133,000. GSA Capital Partners LLP purchased a new position in shares of Y-mAbs Therapeutics during the third quarter valued at about $266,000. Finally, BlackRock Inc. bought a new stake in shares of Y-mAbs Therapeutics in the third quarter worth about $398,000. Hedge funds and other institutional investors own 25.41% of the company’s stock.
YMAB stock opened at $26.78 on Friday. Y-mAbs Therapeutics, Inc has a fifty-two week low of $15.17 and a fifty-two week high of $31.00. The firm has a market capitalization of $903.74 million and a P/E ratio of -17.85.
Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Friday, March 22nd. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.11). As a group, research analysts predict that Y-mAbs Therapeutics, Inc will post -1.67 EPS for the current year.
A number of equities research analysts recently commented on the company. HC Wainwright began coverage on Y-mAbs Therapeutics in a research report on Monday, April 1st. They issued a “buy” rating and a $36.00 target price on the stock. Zacks Investment Research upgraded Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, March 15th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Y-mAbs Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $30.00.
WARNING: “American International Group Inc. Acquires Shares of 4,585 Y-mAbs Therapeutics, Inc (YMAB)” was originally reported by Stock Observer and is the property of of Stock Observer. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.thestockobserver.com/2019/04/07/american-international-group-inc-acquires-shares-of-4585-y-mabs-therapeutics-inc-ymab.html.
Y-mAbs Therapeutics Profile
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Featured Story: Stop Order
Want to see what other hedge funds are holding YMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Y-mAbs Therapeutics, Inc (NASDAQ:YMAB).
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.